184 related articles for article (PubMed ID: 3257159)
1. Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors.
Papa MZ; Yang JC; Vetto JT; Shiloni E; Eisenthal A; Rosenberg SA
Cancer Res; 1988 Jan; 48(1):122-9. PubMed ID: 3257159
[TBL] [Abstract][Full Text] [Related]
2. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
3. Therapy of advanced solid tumors in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells.
Kedar E; Ben-Aziz R; Shiloni E
Isr J Med Sci; 1988; 24(9-10):494-504. PubMed ID: 3264551
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
5. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Lafreniere R; Rosenberg SA
J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
[TBL] [Abstract][Full Text] [Related]
6. Cure of B16F10 melanoma lung metastasis in mice by chronic indomethacin therapy combined with repeated rounds of interleukin 2: characteristics of killer cells generated in situ.
Lala PK; Parhar RS
Cancer Res; 1988 Mar; 48(5):1072-9. PubMed ID: 3124954
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of the tumor determines the outcome of immunotherapy with interleukin-2, ABPP, and cyclophosphamide of micro- and macrometastatic intraperitoneal tumor.
Eggermont AM; Sugarbaker PH
Cancer Detect Prev; 1990; 14(4):483-90. PubMed ID: 2224911
[TBL] [Abstract][Full Text] [Related]
8. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
Naito K; Pellis NR; Kahan BD
Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
[TBL] [Abstract][Full Text] [Related]
9. Enhanced antitumor immune responses of IL-2 gene-modified tumor vaccine by combination with IL-1 and low dose cyclophosphamide.
Cao X; Zhang W; Wan T; Yu Y; Tao Q; Wang J
J Exp Clin Cancer Res; 1999 Jun; 18(2):173-9. PubMed ID: 10464704
[TBL] [Abstract][Full Text] [Related]
10. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
[TBL] [Abstract][Full Text] [Related]
11. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo.
Krosnick JA; Mulé JJ; McIntosh JK; Rosenberg SA
Cancer Res; 1989 Jul; 49(14):3729-33. PubMed ID: 2736513
[TBL] [Abstract][Full Text] [Related]
12. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
Ettinghausen SE; Rosenberg SA
Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
[TBL] [Abstract][Full Text] [Related]
14. Addition of interleukin 12 to low dose interleukin 2 treatment improves antitumor efficacy in vivo.
Leder GH; Oppenheim M; Rosenstein M; Lotze MT; Beger HG
Z Gastroenterol; 1995 Sep; 33(9):499-502. PubMed ID: 8525651
[TBL] [Abstract][Full Text] [Related]
15. Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy.
Futami H; Jansen R; MacPhee MJ; Keller J; McCormick K; Longo DL; Oppenheim JJ; Ruscetti FW; Wiltrout RH
J Immunol; 1990 Dec; 145(12):4121-30. PubMed ID: 2258610
[TBL] [Abstract][Full Text] [Related]
16. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2.
Mulé JJ; Yang JC; Afreniere RL; Shu SY; Rosenberg SA
J Immunol; 1987 Jul; 139(1):285-94. PubMed ID: 3108401
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen potentiates in vivo antitumor activity of interleukin-2.
Kim B; Warnaka P; Konrad C
Surgery; 1990 Aug; 108(2):139-44; discussion 144-5. PubMed ID: 2382215
[TBL] [Abstract][Full Text] [Related]
18. Therapy of disseminated NK-resistant tumor by the synergistic effects of recombinant interleukin-2 and tumor necrosis factor.
Agah R; Malloy B; Sherrod A; Bean P; Girgis E; Mazumder A
J Biol Response Mod; 1988 Apr; 7(2):140-51. PubMed ID: 3258905
[TBL] [Abstract][Full Text] [Related]
19. Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2.
Thompson JA; Peace DJ; Klarnet JP; Kern DE; Greenberg PD; Cheever MA
J Immunol; 1986 Dec; 137(11):3675-80. PubMed ID: 3491145
[TBL] [Abstract][Full Text] [Related]
20. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations.
Evans R; Fuller JA; Christianson G; Krupke DM; Troutt AB
Cell Immunol; 1997 Jul; 179(1):66-73. PubMed ID: 9259773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
